Miltenyi Biotec acquired the lentiviral vector manufacturing business and related assets from Lentigen. According to Miltenyi officials, the deal further strengthens Miltenyi Biotec's portfolio in cell and gene therapy. Assets obtained in the transaction include intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec and operate through its newly formed, wholly owned U.S. subsidiary Lentigen Technology, based in Gaithersburg, MD.
Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies, explained Stefan Miltenyi, CEO of Miltenyi Biotec.
"It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale," he said. "We have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner."